Impact of sorafenib on postoperative complications in thoracic surgery: A single-institution retrospective review

Résumé fourni par la source

Background Sorafenib (SFN) is known to cause postoperative complications, such as delayed wound healing, particularly in abdominal surgeries. However, its effects on thoracic surgeries remain unclear. This study examines the impact of SFN on postoperative outcomes in thoracic surgery. Methods A retrospective comparative study was conducted at Kanagawa Children’s Medical Center from January 2013 to July 2021. The study included patients who underwent thoracic surgery for thoracic or mediastinal metastases of hepatoblastoma. Patients were divided into SFN and non-SFN groups based on whether they received SFN. Repeated surgeries on the same patient were analyzed as separate procedures. Results A total of 18 patients (83 surgeries) were included: 11 patients (35 surgeries) in the SFN group and 16 patients (48 surgeries) in the non-SFN group. Five patients in the SFN group exhibited six postoperative complications, including pneumothorax ( n = 3), wound dehiscence ( n = 2), and postoperative bleeding ( n = 1). In contrast, complications occurred in two patients in the non-SFN group: pneumothorax ( n = 1) and wound infection ( n = 1). The pneumothorax case in the non-SFN group was attributed to positive-pressure ventilation during contralateral surgery. In the SFN group, one case had the same cause, while two cases developed as late-onset pneumothorax after hospital discharge. Conclusion Patients receiving SFN may develop late-onset pneumothorax. These findings highlight the need for careful postoperative management in patients undergoing thoracic surgery while on SFN therapy.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.